To include your compound in the COVID-19 Resource Center, submit it here.

Room for one more in RA

Pharmacia Corp., which is building an inflammation portfolio, is betting that Celltech Group plc's CDP 870 will be competitive in rheumatoid arthritis, even though it would be the third anti-TNF product to reach the market for RA. Celltech and PHA

Read the full 400 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers